显微镜
发表于 2025-3-25 06:05:37
Roles of Microglia in Spinal Cord Injuryole in controlling cell growth, proliferationand survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in human cancercells has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents.Although often non-selective for the intended
cognizant
发表于 2025-3-25 10:10:22
http://reply.papertrans.cn/23/2211/221038/221038_22.png
非秘密
发表于 2025-3-25 11:39:07
Kenzo Uchida,Masaya Nakamura,Yoshiaki Toyamaical background of HDACs and their link to cancer andcancer treatment. The body of the work consists of a categorized and chronological medicinal chemistryoverview. This part describes key medicinal chemistry contributions ranging from the very early HDAC inhibitorsto compounds currently in the clin
包租车船
发表于 2025-3-25 15:56:10
https://doi.org/10.1007/978-981-99-7269-2 of the molecular mechanisms underlyingthe angiogenesis process have led to the discovery of a variety of pharmaceutical agents withantiangiogenic activity. The potential application of these angiogenesis inhibitors is currentlyunder intense clinical investigation. Decades of investigation suggest t
推延
发表于 2025-3-25 20:32:50
http://reply.papertrans.cn/23/2211/221038/221038_25.png
Valves
发表于 2025-3-26 00:15:31
http://reply.papertrans.cn/23/2211/221038/221038_26.png
harrow
发表于 2025-3-26 07:44:06
http://reply.papertrans.cn/23/2211/221038/221038_27.png
纺织品
发表于 2025-3-26 12:03:03
http://reply.papertrans.cn/23/2211/221038/221038_28.png
葡萄糖
发表于 2025-3-26 15:35:59
Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK,significant number of kinase inhibitors have recentlyentered clinical practice for the treatment of a variety of cancers and many others are in advancedstages of clinical research. Among these are several promising agents that act in the pathway that initiateswith the growth factor receptors EGFR/Er
deriver
发表于 2025-3-26 18:54:31
Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress inl-molecule inhibitors that could be developedas oral therapeutics. There are now several farnesyl protein inhibitors (FTIs) in various phases of clinicaldevelopment and at least two compounds have entered phase III. The published data suggest some disappointingactivity in the major solid tumors, wit